L Cöster

Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden

Johan Askling, C. Michael Fored, Lena Brandt et al. · Arthritis & Rheumatism · 2005 · 414 citations

Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists

Johan Askling, C. Michael Fored, L. Brandt et al. · Annals of the Rheumatic Diseases · 2007 · 334 citations · Full text

Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial

Ronald van Vollenhoven, Sofia Ernestam, P. Geborek et al. · The Lancet · 2009 · 316 citations

Inflammation, Rheumatology, Rheumatoid Disorder +12

Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register

Johan Askling, Eva Baecklund, Fredrik Granath et al. · Annals of the Rheumatic Diseases · 2008 · 259 citations

Cancer risk in patients with rheumatoid arthritis treated with anti–tumor necrosis factor α therapies: Does the risk change with the time since start of treatment?

Johan Askling, Ronald van Vollenhoven, Fredrik Granath et al. · Arthritis & Rheumatism · 2009 · 240 citations

Epidemiology Of Cancer, Immunology, Pharmacotherapy +22